): Protocol Review & Monitoring System Norris Cotton Cancer Center (NCCC) has established a process by which Cancer Center Members undergo internal peer review of the scientific merit and prioritization of proposed clinical trials and population science protocols prior to Institutional Review Board review (i.e., Dartmouth's Committee for the Protection of Human Subjects [CPHS]). These NCCC reviews are to confirm the scientific validity of the proposed study, to assess the feasibility of the study in light of the availability of human subjects and current protocols relying on enrollments from that same population, to assure the safety monitoring plan is appropriate and in accordance with regulations, and to offer comments that could enhance either scientific merit or implementation logistics of the planned study. NCCC's Clinical Cancer Research Committee (CCRC) is a chartered multidisciplinary committee charged with reviewing all non-NCI Cooperative group research protocols and amendments proposed to be opened by Dartmouth Principal Investigators (PIs) for treatment of, and intervention for, cancer. Cancer prevention studies, screening trials, behavioral studies, quality of life / survivorship studies, and interventional trials that rely on collection of patient-reported outcomes that have not already undergone external peer review by NIH and its funding agencies are reviewed by the CCRC Population Science Subcommittee (PSS). The CCRC has the authority to approve, require modifications in, or disapprove research activities that fall within its jurisdiction. CCRC members are selected to represent the broad spectrum of oncology research. Cadre membership includes representatives from medical oncology, hematology, surgical oncology, pediatric oncology, clinical pharmacology, biostatistics, basic science research, population science, clinical research administration, and patient advocacy. Other disciplines such as Radiation Oncology, Pathology and Immunology are represented by members on an ad-hoc basis when a clinical trial features such components in its main objectives.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA023108-39
Application #
9404368
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
Project End
Budget Start
2017-12-01
Budget End
2018-11-30
Support Year
39
Fiscal Year
2018
Total Cost
Indirect Cost
Name
Dartmouth College
Department
Type
DUNS #
041027822
City
Hanover
State
NH
Country
United States
Zip Code
Barr, Fiona D; Ochsenbauer, Christina; Wira, Charles R et al. (2018) Neutrophil extracellular traps prevent HIV infection in the female genital tract. Mucosal Immunol 11:1420-1428
Jackson, Brian P (2018) Low level determination of gallium isotopes by ICP-QQQ. J Anal At Spectrom 33:897-900
Rahme, Gilbert J; Luikart, Bryan W; Cheng, Chao et al. (2018) A recombinant lentiviral PDGF-driven mouse model of proneural glioblastoma. Neuro Oncol 20:332-342
Wang, Zhaoxi; Wei, Yongyue; Zhang, Ruyang et al. (2018) Multi-Omics Analysis Reveals a HIF Network and Hub Gene EPAS1 Associated with Lung Adenocarcinoma. EBioMedicine 32:93-101
Sergent, P A; Plummer, S F; Pettus, J et al. (2018) Blocking the VISTA pathway enhances disease progression in (NZB?×?NZW) F1 female mice. Lupus 27:210-216
Kachuri, Linda; Saarela, Olli; Bojesen, Stig Egil et al. (2018) Mendelian Randomization and mediation analysis of leukocyte telomere length and risk of lung and head and neck cancers. Int J Epidemiol :
Rodriguez-Garcia, Marta; Fortier, Jared M; Barr, Fiona D et al. (2018) Aging impacts CD103+ CD8+ T cell presence and induction by dendritic cells in the genital tract. Aging Cell 17:e12733
Shajani-Yi, Zahra; de Abreu, Francine B; Peterson, Jason D et al. (2018) Frequency of Somatic TP53 Mutations in Combination with Known Pathogenic Mutations in Colon Adenocarcinoma, Non-Small Cell Lung Carcinoma, and Gliomas as Identified by Next-Generation Sequencing. Neoplasia 20:256-262
Shee, Kevin; Jiang, Amanda; Varn, Frederick S et al. (2018) Cytokine sensitivity screening highlights BMP4 pathway signaling as a therapeutic opportunity in ER+ breast cancer. FASEB J :fj201801241R
Bossé, Yohan; Amos, Christopher I (2018) A Decade of GWAS Results in Lung Cancer. Cancer Epidemiol Biomarkers Prev 27:363-379

Showing the most recent 10 out of 1911 publications